Health

The answer is provided by EFPIA’s annual WAIT indicator (press release, report). First, we see a large decrease in the share of pharmaceuticals fully availbity, drive by a small increase in reduced availability but a much larger increase in the number of drugs that only have a limited availability. Specifically, Historically full availability was the…

At least, it won’t be overturned by the US Supreme Court. Endpoints reports: The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Novartis and Boehringer Ingelheim… The…

If you are a payer or a policymaker, should you except the results of a global clinical trial or require additional evidence that a drug works in your country.  There are a few options to consider. Delay approval until local confirmatory trial.  Approach enacted in several Asian countries (see Habr et al. 2024).  While this…

That is the title of my latest column in The Evidence Base. In this latest edition of Perspectives from the Healthcare Economist, Jason Shafrin (FTI Consulting and Mann School of Pharmacy, University of Southern California) examines how AI is beginning to reshape health economics and outcomes research (HEOR), from evidence generation and literature reviews to data analysis…

Excited to be attending ISPOR 2026 next week. I’m looking forward to some great plenary sessions, presenting my research on “The Extent of Treatment Response and Preference Heterogeneity in Major Depressive Disorder: Implications for Population-Level Resource Allocation” with co-authors Nadine Zawadzki and Cheryl Neslusan, and meeting up with old colleagues. See you in Philadelphia!